TELA

SEC source: 0001192482-19-000422 · edgar.xml · derivative · entry 4

Greenhalgh Ellis Skott · CIK 0001790671 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,887 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F4 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.

SEC source: 0001192482-19-000422 · edgar.xml · derivative · entry 3

Greenhalgh Ellis Skott · CIK 0001790671 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,025 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.exercise_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.expiration_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F4 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.

SEC source: 0001192482-19-000422 · edgar.xml · nonDerivative · entry 2

Greenhalgh Ellis Skott · CIK 0001790671 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

SEC source: 0001192482-19-000422 · edgar.xml · nonDerivative · entry 1

Greenhalgh Ellis Skott · CIK 0001790671 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,623

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · balance_after: Reflects 5,623 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).

SEC source: 0001192482-19-000419 · edgar.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP IV LLC · CIK 0001502240 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,568,627

F1 · balance_after: Reflects 1,184,012 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).

F2 · ownership.direct: These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV, and OrbiMed Advisors LLC ("Advisors"), a registered advisor under the Investment Advisors Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IV noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee consisting of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI IV.

F3 · ownership.direct: Each of GP IV and Advisors disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001192482-19-000430 · edgar.xml · nonDerivative · entry 1

Quaker BioVentures II LP · CIK 0001497725 · 10% owner

Quaker BioVentures Capital II, L.P. · CIK 0001583083 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 888,664

F1 · balance_after: Reflects 705,530 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).

SEC source: 0001192482-19-000420 · edgar.xml · nonDerivative · entry 1

Oliva Adele C · CIK 0001339379 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Quaker Bioventures II, L.P.

Disclosed balance after: 888,664

F1 · balance_after: Reflects 705,530 shares of common stock received as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).

F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for the purposes of Section 16 or otherwise.

SEC source: 0001192482-19-000428 · edgar.xml · nonDerivative · entry 2

Zuga Matt · CIK 0001790214 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By HighCape Partners QP, L.P.

Disclosed balance after: 260,808

F2 · balance_after: Reflects 183,907 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).

SEC source: 0001192482-19-000428 · edgar.xml · nonDerivative · entry 1

Zuga Matt · CIK 0001790214 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By HighCape Partners, L.P.

Disclosed balance after: 12,675

F1 · balance_after: Reflects 2,455 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).

SEC source: 0001192482-19-000424 · edgar.xml · nonDerivative · entry 2

Azarbarzin Kurt · CIK 0001792303 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By HighCape Partners QP, L.P.

Disclosed balance after: 260,808

F2 · balance_after: Reflects 183,907 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).

SEC source: 0001192482-19-000424 · edgar.xml · nonDerivative · entry 1

Azarbarzin Kurt · CIK 0001792303 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By HighCape Partners, L.P.

Disclosed balance after: 12,675

F1 · balance_after: Reflects 2,455 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).